NGM Biopharmaceuticals, Inc. Common Stock
NGM
NGM was delisted on the 4th of April, 2024.
59 hedge funds and large institutions have $533M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 32 increasing their positions, 8 reducing their positions, and 5 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 8
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
46% more capital invested
Capital invested by funds: $365M → $533M (+$168M)
16% more funds holding
Funds holding: 51 → 59 (+8)
3.36% more ownership
Funds ownership: 39.92% → 43.28% (+3.4%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$24.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.21M |
| 3 |
JP Morgan Chase
New York
|
+$4.14M |
| 4 |
PS
Peter Svennilson
|
+$3.71M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$4.39M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$4.01M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.99M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$3.99M |
| 5 |
JRP
Jasper Ridge Partners
Menlo Park,
California
|
-$629K |
NGM Hedge Fund Activity: Q4 2019 in Review
59 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q4 2019, worth a combined $533M — up 46% from $365M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new NGM positions and 5 closed out — a net gain of 8 holders — while 32 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock, adding an estimated $24.2M. The largest seller was HealthCor Management, exiting entirely with an estimated $4.39M sold.
- 59 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q4 2019, up from 51 in Q3 2019.
- Funds reported $533M of NGM Biopharmaceuticals, Inc. Common Stock stock for Q4 2019, up 46% quarter-over-quarter.
- 13 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q4 2019 and 5 closed out, a net change of +8 holders.
- The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q4 2019 was BlackRock, an estimated $24.2M added.
- The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q4 2019 was HealthCor Management, an estimated $4.39M sold.
Based on aggregated 13F filings for Q4 2019.